-
Mashup Score: 0Margaret Gatti-Mays, MD MPH (@drgattimays.bsky.social) - 7 month(s) ago
Deputy Director @ohiostatemedonc #BreastCancer Section Chief @OSUCCC_James |#immunotherapy | #WomenInMedicine #BoyMom | #NIH alumnus | Posts My Own
Source: bsky.appCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Margaret Gatti-Mays, MD (@drgattimays) • Instagram photos and videos - 7 month(s) ago
35 Followers, 60 Following, 0 Posts – See Instagram photos and videos from Margaret Gatti-Mays, MD (@drgattimays)
Source: www.instagram.comCategories: General Medicine News, Hem/OncsTweet-
Come find me on Instagram 👇 https://t.co/pNStV6n96i
-
-
Mashup Score: 17
Sociodemographic (age, race/ethnicity) and clinical (Eastern Cooperative Oncology Group performance status, pre-existing comorbidities, and active and progressing cancer) risk factors were associated with worse COVID-19 outcomes in patients with breast cancer.
Source: elifesciences.orgCategories: General Medicine News, Hem/OncsTweet-
Congratulations to @COVID19nCCC including @OSUCCC_James coauthors Dr Sachin Jhawar and @StoverLab on this article highlighting worse outcomes for underrepresented racial/ethnic patients with #breastcancer and #COVID - we must do better @OhioStateMedOnc https://t.co/vokdWPxbso
-
-
Mashup Score: 3Full Program - 8 month(s) ago
The San Antonio Breast Cancer Symposium® “An international scientific symposium for interaction and exchange among basic scientists and clinicians in breast cancer.” The San Antonio Breast Cancer Symposium® is presented by the Cancer Therapy & Research Center at UT Health Science Center San Antonio, the American Association for Cancer Research, and Baylor College of Medicine. The driving force behind this collaboration is the shared mission of the organizations to advance progress against brea
Source: sabcs.orgCategories: General Medicine News, Hem/OncsTweet-
Always excited to see the full program for @SABCSSanAntonio and start to plan 🎉 https://t.co/p0ewvGnpXm
-
-
Mashup Score: 3Full Program - 8 month(s) ago
The San Antonio Breast Cancer Symposium® “An international scientific symposium for interaction and exchange among basic scientists and clinicians in breast cancer.” The San Antonio Breast Cancer Symposium® is presented by the Cancer Therapy & Research Center at UT Health Science Center San Antonio, the American Association for Cancer Research, and Baylor College of Medicine. The driving force behind this collaboration is the shared mission of the organizations to advance progress against brea
Source: sabcs.orgCategories: General Medicine News, Hem/OncsTweet-
Always excited to see the full program for @SABCSSanAntonio and start to plan 🎉 https://t.co/p0ewvGnpXm
-
-
Mashup Score: 9Ohio State News - 8 month(s) ago
Welcome to Ohio State News. The Ohio State University offers expertise on a variety of topics. Find news stories about science and medicine, arts and humanities, Buckeye sports, research, students, health, and campus life. Ohio State News delivers timely, trustworthy news to connect you to Ohio State’s impact on your life, your community and your world.
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet-
RT @OhioStateAlumni: Catch @TBDBITL Skull Session from wherever you are at https://t.co/nDwoa6lJqa Today's show will start at approx. 9:30…
-
-
Mashup Score: 26Cancer Immunotherapy Trials Network 12: Pembrolizumab in HIV-Associated Kaposi Sarcoma | Journal of Clinical Oncology - 9 month(s) ago
PURPOSECancer Immunotherapy Trials Network 12 demonstrated safety of pembrolizumab in treating advanced cancer in people with HIV. Here, we report results of the Kaposi sarcoma (KS) cohort.METHODSIn this multicenter phase I trial, we enrolled participants …Phase I study CITN12: pembrolizumab in HIV+ Kaposi sarcoma is safe, durable responses in 62% of patients.
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
So incredibly proud of @DrKateLurain and @ramya_ramaswami (among other coauthors) for this incredible contribution to #HIVOnc 👏👏👏 #IO @JCO_ASCO Cancer Immunotherapy Trials Network 12: Pembrolizumab in HIV-Associated Kaposi Sarcoma https://t.co/jbaHMgGZpY
-
-
Mashup Score: 25Cancer Immunotherapy Trials Network 12: Pembrolizumab in HIV-Associated Kaposi Sarcoma | Journal of Clinical Oncology - 9 month(s) ago
PURPOSECancer Immunotherapy Trials Network 12 demonstrated safety of pembrolizumab in treating advanced cancer in people with HIV. Here, we report results of the Kaposi sarcoma (KS) cohort.METHODSIn this multicenter phase I trial, we enrolled participants …Phase I study CITN12: pembrolizumab in HIV+ Kaposi sarcoma is safe, durable responses in 62% of patients.
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
So incredibly proud of @DrKateLurain and @ramya_ramaswami (among other coauthors) for this incredible contribution to #HIVOnc 👏👏👏 #IO @JCO_ASCO Cancer Immunotherapy Trials Network 12: Pembrolizumab in HIV-Associated Kaposi Sarcoma https://t.co/jbaHMgGZpY
-
-
Mashup Score: 46Researcher creates new immunotherapy for breast cancer - 9 month(s) ago
Patients @OSUCCC_James are the first to enroll in a clinical trial testing a new immunotherapy combination for metastatic breast cancer.
Source: health.osu.eduCategories: General Medicine News, Hem/OncsTweet-
Immunotherapy for breast cancer | Ohio State Health & Discovery @OSUCCC_James @OhioStatePIIO @OSUWexMed #IO #BreastCancer @theNCI https://t.co/h56J0U4ojV
-
-
Mashup Score: 45Researcher creates new immunotherapy for breast cancer - 9 month(s) ago
Patients @OSUCCC_James are the first to enroll in a clinical trial testing a new immunotherapy combination for metastatic breast cancer.
Source: health.osu.eduCategories: General Medicine News, Hem/OncsTweet-
Immunotherapy for breast cancer | Ohio State Health & Discovery @OSUCCC_James @OhioStatePIIO @OSUWexMed #IO #BreastCancer @theNCI https://t.co/h56J0U4ojV
-
Come find me on BlueSky as well at the same handle 🦋 https://t.co/uxZ6lJ0tUR